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The Wnt/β-catenin signaling is an essential pathway involved in cell cycle 
control.  Dysregulation of Wnt/β-catenin signaling pathway has been reported during 
viral infections. In this study, we examined the effect of modulating Wnt/β-catenin 
signaling during influenza virus infection. The activation of the Wnt/β-catenin pathway 
with Wnt3a increased mRNA expression of influenza virus genes in vitro in mouse lung 
epithelial E10 cells and in vivo in the lungs of mice infected with influenza virus 
A/Puerto Rico/8/34. However, inhibition of Wnt/β-catenin signaling with iCRT14 
reduced virus titer and viral gene expression in human lung epithelial A549 cells and 
viral replication in primary mouse alveolar epithelial cells infected with influenza virus 
A/Puerto Rico/8/34 and A/WSN/1933. iCRT14 acts at the early stage of virus replication 
and its anti-viral activity is independent of interferon response. Treatment with iCRT14 
inhibited the expression of viral genes (vRNA, cRNA and mRNA) evaluated. 
Intraperitoneal administration of iCRT14 reduced viral load, improved clinical 
symptoms, and partially protected mice from influenza virus infection.  
Long non-coding RNAs (lncRNAs) are a new arm of gene regulatory mechanism 
as discovered by sequencing techniques and functional studies. There are only few 
studies on lncRNAs as related to gene expression regulation and anti-viral activity during 
influenza virus infection. Using RNA sequencing analysis, we found that 1,912 lncRNAs 
were significantly changed in human lung epithelial A549 cells infected with influenza 
A/Puerto Rico/8/34 along with high enrichment of type I interferon signaling and cellular 
response genes based on Go ontology. Seven selected up-regulated lncRNAs were 
verified by real-time PCR and were also induced by other two influenza H1N1 virus 
strains (A/WSN/1933 and A/Oklahoma/3052/09) and interferon β1. Knockdown of TAP1 
and PSMB8 antisense RNA 1 (TAPSAR1) using lentiviral shRNA reduced the release of 
progeny influenza virus particles and inhibited viral protein synthesis but had no effects 
on viral mRNA level in single-cycle and multi-cycle infections. Knockdown of 
TAPSAR1 did not change the expression level of its neighboring gene PSMB8, but 
markedly reduced interferon gamma-induced protein 10 expression. Our study suggests 
that lncRNA TAPSAR1 could be a new host factor target for developing antiviral therapy 
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1.1 Influenza virus 
Influenza virus is a single stranded, negative sense RNA virus belonging to the 
Orthomyxoviridae family. It has 8 genome segments, which encode 10 - 12 different proteins (1). The 
replication mechanism of the virus is error-prone, resulting in mutations in the genome of the virus (2, 
3). These changes lead to the development of antiviral drug resistance against most of the current 
antivirals drugs available in the market and is the reason for new influenza virus vaccines each season 
due to antigenic shift (4). Antigenic drift results from gradual point mutations in surface antigens 
during replication of the virus, whereas antigenic shift occurs due to genetic reassortment when two 
different influenza viruses infect the same cell. Antigenic shift causes the emergence of pandemic 
strains of virus, which can potentially infect huge populations of humans and animals (5). 
Use of vaccine during the pandemics has many limitations such as lag time in vaccine 
production, efficacy of the vaccine in the population and access to the vaccine during pandemics (6). 
Thus, patient care depends upon the availability of effective antiviral drugs. However, emerging 
influenza viruses become resistant to the current antivirals because they target the viral proteins (7, 8).   
The FDA-approved drugs, adamantane and oseltamivir target M2 ion channel and neuraminidase, 




anti-influenza virus drugs (9-12), but have the same limitation of drug resistance. Due to its small 
genome size, influenza virus is dependent on the host cell machinery for its replication from virus 
entry to exit from the host cells. Many host factors  utilized by influenza virus have been identified at 
various stages of the virus life cycle (13, 14). Targeting these factors for developing antivirals can 
overcome the limitation of drug resistance of the current anti-influenza virus drugs. 
 
1.2 Wnt signaling pathway  
The Wnt/β-catenin signaling pathway plays an important role in cellular development and 
differentiation and has been implicated in developmental diseases and cancer (15). This pathway is 
activated by binding of Wnt ligands to the Frizzled receptor. In the absence of Wnt ligands, the 
central component, β-catenin is marked by ubiquitination for degradation via the destruction complex 
composed of adenomatous polyposis coli (APC), axin and glycogen synthase kinase 3β (GSK3β). 
When Wnt ligands are present, the complex is destabilized, leading to the accumulation and nuclear 
translocation of cytosolic β-catenin. In the nucleus, β-catenin interacts with the T cell factor/lymphoid 
enhancer binding factor 1 (TCF/LEF) transcription factor to activate Wnt target genes. iCRT14 is 
specific inhibitor of Wnt/β-catenin signaling which disrupts the direct interaction between β-catenin 
and TCF4/LEF1(16). This inhibitor also prevents the binding of TCF4 to DNA; however, iCRT14 
does not affect non-canonical Wnt signaling and other pathways such as Hedgehog, JAK/STAT and 
notch signaling (16). 
 There are several studies regarding the interaction of the Wnt/β-catenin signaling pathway 
and viruses including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). HIV’s 
negative regulatory factor (Nef) protein interacts with β-catenin to inhibit Wnt/β-catenin signaling 
(17). The core protein and nonstructural NS5A protein of HCV activate the Wnt/β-catenin signaling 
pathway (18) (19). Kumar et al. has shown that activation of Wnt/β-catenin with lithium chloride 
(LiCl) reduces HIV propagation in peripheral mononuclear cells (20) and Narasipura et al. has 




on the role of Wnt/β-catenin signaling in influenza virus infection are very limited. In this study, we 
investigated the effect of Wnt/β-catenin signaling activation and inhibition on influenza virus 
infection. 
 
1.3 Long-non coding RNAs  
Only approximately 2% of human genome is used for protein-coding genes (22). Recent 
advances in sequencing technologies have enabled the discovery of vast portions of non-coding 
transcripts. Long non-coding RNAs (lncRNAs) are non-coding transcripts that have a length of > 200 
nucleotides and do not encode any proteins. Although very few lncRNAs have been studied, 
lncRNAs play roles in development and diseases. LncRNA expression shows greater cell- and tissue-
specificity than protein-coding genes (23, 24). The number of lncRNAs increases with developmental 
complexity (25), leading to the idea that lncRNAs play an important role in giving rise to the diversity 
of cell differentiation programs underlying development in multicellular organisms. Dysregulation of 
lncRNAs has been observed under many pathological conditions including respiratory diseases (26), 
cancers (27, 28) and heart diseases (29), indicating that abnormal expression of lncRNAs contributes 
to the development of pathophysiological conditions. 
 
1.4 Function of lncRNAs 
The functions of lncRNAs are diverse including chromatin remodeling, transcription and post 
transcription regulation, decoying, scaffolding, and microRNA sponging. Examples of epigenetic 
gene regulation by lncRNAs are X-inactive specific transcript (Xist) and HOX transcript antisense 
RNA (HOTAIR). They define epigenetic changes by interacting with various chromatin modifiers to 
alter their structure and in turn govern the accessibility of DNA to transcription factors and 
polymerase (27, 30).  One example where lncRNA can directly interfere with polymerase II (Pol II) 
activity is the inhibition of the major coding transcript of dihydrofolate reductase (DHFR) (31). In 




formation of the transcription preinitiation complex at the major promoter. Several lncRNAs act as 
RNA decoys. These lncRNAs titrate transcription factors away from their DNA targets by directly 
binding to them and thus suppress the transcription. LncRNA PANDA is one such example, which 
sequester nuclear transcription factor Y, alpha (NF-YA) away from its pro-apoptotic gene (32). At the 
post-transcriptional level, lncRNAs can function as microRNA target site decoys, titrating microRNA 
effector complexes away from their mRNA targets. For example, the tumor suppressor pseudogene 
PTENP1 sequesters miR-19b and miR-20a to regulate the target gene expression of these microRNAs 
(33). LncRNAs also act as a scaffold by binding specific combinations of regulatory proteins, 
enforcing a transcription silent state or contributing to the assembly of DNA–RNA–protein 
interactions at specific transcribed locations. Two lncRNAs, Mistral and HOTTIP, have been 
implicated in recruiting MLL, an H3K4 trimethylase to chromatin (34, 35). 
 
1.5 LncRNAs in innate and adaptive immune signaling  
The innate and adaptive immune responses provide immunity against a variety of pathogens. 
Innate immunity presents the first line of defense against pathogens. LncRNAs such as THRIL (36), 
lincRNA-Cox2, Lethe (37) and PACER (38) have been shown to regulate gene expression in innate 
immune cells. LincRNA-Cox2 regulates the expression of different sets of inflammatory genes in 
unstimulated and TLR2 ligand-stimulated macrophage cell line. The silencing of lincRNA-Cox2 up-
regulates certain chemokines (CCL5, CX3CL1), chemokine receptors (CCR1), and interferon-
stimulated genes (ISGs) (IRF7, OAS1A, OAS1L, OAS2, IFI204 and ISG15) in the unstimulated 
cells, but down-regulates TLR1, IL6 and IL23 in the stimulated cells. This negative regulation of the 
genes is dependent on the interactions of lincRNA-Cox2 with heterogeneous nuclear 
ribonucleoprotein A/B and A2/B1 (39). Adaptive response is orchestrated through T and B 
lymphocytes. LncRNAs play a role in lineage-specific differentiation and activation of these cells. 
Several studies highlight the role of lncRNA in adaptive immune response including NRON (40), 




results in impaired recruitment of TH2 cells to the lungs (44). LincR-Ccr2-5′AS is expressed 
specifically on TH2 subset of helper T cells and is regulated by GATA-3 transcription factor. 
 
1.6 LncRNAs and influenza virus 
The roles of lncRNAs in viral infections have been documented (45-50). Negative regulator 
of antiviral response (NRAV) is a lncRNA that is downregulated by various viruses including 
influenza virus, sendai virus, muscovy duck reovirus, and herpes simplex virus (48). Overexpression 
of NRAV increases virus replication whereas knockdown of NRAV has an opposite effect. The 
down-regulation of NRAV by influenza virus infection activates the marks of transcription 
(H3K4m3) and a decrease in repression signal of transcription (H3K27m3) at mxA and ifitm3 
transcription start sites and thus regulates histone modification of these genes. Nuclear enriched 
abundant transcript 1 (NEAT1) upregulates interleukin-8 (IL8) transcription during influenza virus 
infection by recruiting splicing factor proline/glutamine-rich (SFPQ/PSF) to nuclear paraspeckle 
bodies (51). Gene regulation by lncRNA can also take place in a locus-specific manner. BST2 
Interferon Stimulated Positive Regulator (BISPR) acts as a positive regulator of the flanking antiviral 
gene, bone marrow stromal cell antigen 2 (BST2) and dictates the potency of the antiviral interferon 
(IFN) response (52). Virus inducible lncRNA (VIN) is highly induced by influenza A virus and 
vesicular stomatitis virus, but not by interferons and is required for influenza virus replication (50). 
These studies suggest that lncRNAs play a crucial role in influenza virus pathogenesis.  
Therefore, we perform studies to find out role of Wnt signaling and lncRNA in influenza 
virus infection with following objectives.  
1.7 Objectives of the study 
The objectives of these studies were to address the effect of Wnt signaling and iCRT14 on 
influenza virus replication and to find lncRNAs that are dysregulated during influenza virus infection. 







MATERIALS AND METHODS 
 
2.1 Cell Culture  
A549 (human lung epithelial), human embryonic kidney (HEK) epithelial 293T and 
MDCK (Madin-Darby canine kidney epithelial) cells were purchased from ATCC (Manassas, 
VA). A549 cells were maintained in F12K medium with 10% fetal bovine serum (FBS) and 1% 
penicillin and streptomycin (PS). HEK, MDCK and Vero (African green monkey kidney 
epithelial) cells (ATCC) were maintained in DMEM with 10% FBS and 1% PS.  E10 cells, a lung 
epithelial cell line, were kindly provided by Dr. M. Williams (Boston University) and were 
maintained in CMRL medium with 10% FBS, 1% PS and 2.5 mM L-Glutamax®. 
2.2 Isolation of mouse primary epithelial cells. 
Mouse alveolar epithelial cells type II (AEC II) were isolated from male C57BL/6 mice 
(8-10 weeks of age) as previously described (53). All the animal experiments were approved by 
the Institutional Animal Care and Use Committee (IACUC) at Oklahoma State University. Mice 
were anesthetized with ketamine and xylazine. The abdominal cavity was opened, and mice were 
exsanguinated by interrupting the abdominal aorta at the base of the heart and the lungs were 
cannulated with a 20-gauge catheter via the trachea. Lungs were perfused with solution II (10 




0.1 mg/ml streptomycin sulfate, 0.06 mg/ml penicillin G, 3 mM Na2HPO4 and 3 mM NaH2PO4), 
followed by instilling 1 ml of solution I (15 ml solution II plus 10 ml dispase from stock of 50 
caseinolytic units/ml) through the trachea. Three lungs were isolated, pooled into a beaker 
containing ~10 ml of the solution I and incubated at 37°C for 45 min to release the AECs. After 
incubation, the lungs were chopped and further digested with the addition of DNase I (100 μg/ml) 
to solution I (10 ml) for 45 min at 37°C, with intermittent shaking. The digested lungs were 
filtered through 160-, 37- and 15-μm gauge nylon mesh sequentially. The filtrate was centrifuged 
at 250 g for 10 min. The cell pellet was resuspended in DMEM and incubated in a 100-mm-
diameter Petri dish coated with mouse IgG (75 μg per dish) for 1 h. The cells were spun down at 
250 g for 10 min and resuspended in DMEM containing 10% FBS. The yield was ~10×106 cells 
per 3 mice and the cell viability was >95%.  
2.3 Preparation of Wnt3a Conditioned Medium 
A stable cell line expressing soluble murine Wnt3a and a control murine L-cell line 
(ATCC) were maintained in DMEM supplemented with 10% FBS, 1% L-glutamine, and 
0.4 mg/ml G418 (Invitrogen, Carlsbad, CA). To obtain Wnt3a_, or control (Con)_conditioned 
medium (CM), cells were cultured in fresh growth medium (DMEM with 10% FBS) without 
G418 for 4 days and then fresh G418-free medium for additional 3 days. The cultured media were 
mixed, sterile-filtered, and stored at −80°C until use. The activity of Wnt3a_CM was determined 
by a TOPflash assay performed in HEK 293T cells. Wnt3a_CM normally showed an 
approximately sevenfold increase in the reporter activity compared with Con_CM. 10X 
Wnt3a_CM or Con-CM were prepared by concentrating 20 ml CM into 2 ml using an 







2.4 Influenza virus stocks 
Stocks of H1N1 strains of influenza virus A/PuertoRico/8/34 (A/PR/8/34), A/WSN/1933 
(WSN) and A/Oklahoma/3052/09 (Pdm/OK) were propagated in the allantoic cavity of 10-day 
specific-pathogen-free embryonated chicken eggs (Charles River Laboratories, MA) at 35°C. The 
allantoic fluid was harvested, centrifuged at 2,000 g for 10 min, and stored at −80°C. Virus titer 
was determined by a Tissue Culture Infective Dose (TCID50) assay. Briefly, MDCK cells were 
seeded in 96 well plates at a density of 25,000 cells per well. The next day cells were washed 
with serum-free medium twice. A series of ten-fold dilutions ranging from 10-1 to 10-8 were 
prepared in serum-free medium with 2 µg/ml L-1-Tosylamide-2-phenylethyl chloromethyl ketone 
treated trypsin (TPCK-trypsin). Cells were infected with each diluted virus stock in triplicate. 
After a 72 h culture, cells were analyzed for cytopathic effect (CPE) and TCID50 was calculated 
using the Reed-Muench method (54).   
 
2.5 Virus infection of the cells 
Primary AEC II (0.25 × 106/well) were cultured in type I collagen-coated 12-well plates 
or cover slips for 6 days. All other cells were seeded at a density of 0.5 × 106 per well in 6-well 
plates for 24 h. The cells were washed with serum-free medium twice. The cells were infected 
with A/PR/8/34 or A/WSN/33 virus in serum-free medium containing TPCK-Trypsin (2 µg/ml) 
at a desired multiplicity of infection (MOI) at 37°C and 5% CO2 incubator for 1 h. The cells were 
then washed with PBS once and complete medium was added. At 24 hrs post infection total viral 
mRNAs in cells and virus titers in media were determined.  
 
2.6 Immunofluorescence  
Alveolar epithelial cells were fixed with ice-cold 4% paraformaldehyde for 20 min and 




washed again and blocked with 5% goat serum. Cells were then incubated with hamster anti-T1α 
antibody (1:100 dilutions; E11, Developmental Studies Hybridoma Bank, University of Iowa) at 
4˚C overnight, followed by incubation with Alexa fluor-488-conjugated anti-hamster secondary 
antibody (Life Technologies, Grand Island, NY) at 1:500 dilutions. Finally, cells were stained 
with 4' with 6-diamidino-2-phenylindole dihydrochloride (DAPI). Coverslips were mounted on 
glass slides for imaging.   
 
2.7 Cell viability assay 
iCRT14 (Tocris Bioscience, Minneapolis, MN) stock solution was prepared at 25 mM in 
dimethyl sulfoxide (DMSO) and then diluted to desired concentrations with respective media for 
different cell types. DMSO (0.05%) was used as a vehicle control. For cell viability assay A549 
cells were seeded in 96 well plates at a density of 104/well. The next day, cells were treated with 
12.5 µM iCRT14.  The cells were collected at different times and cell viability was determined 
with CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI). This assay 
measures viable cells based on metabolic activity of the cells by quantifying cellular ATP content 
by luminescent signal.   
 
2.8 RNA isolation and quantitative real-time PCR 
Total RNAs were extracted using TRI Reagent (Molecular Research Center, Cincinnati, 
OH) and treated with DNase (Ambion, Grand Island, NY). For host mRNA, 1 µg of RNA was 
reverse-transcribed into cDNA using Oligo dT and random primers. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a housekeeping gene control. Different types of viral 
RNAs were quantified as described (55). One µg RNA was reverse-transcribed using strand- and 
sense-specific primers for vRNA (5’-AGCGAAAGCAGG-3’ and 5’-AGCAAAAGCAGG-3’), 
cRNA (5’-AGTAGAAACAAGG-3’), and mRNA (Oligo dT). GAPDH specific primer (5’-




used in this study are listed in Table 1. Real-time PCR was carried out with a 20 μl reaction 
mixture, which contained specific primers with SyBR green DNA dye (AnaSpec, Fremont, CA). 
The PCR conditions were performed on a 7900HT Fast Real-Time PCR System (Applied 
Biosystem, Foster City, CA) at cycling conditions of 95°C for 2 min, and 40 cycles of 95°C for 

























Table 1. Real-time PCR primers  
 
Gene Name Forward primer Reverse primer 
PB1 GTCGAAAGGCTAAAGCATGGA TGGCACTGAGATCTGCATGAC 
PB2 CCGATGCCATAGAGGTGACA GGAGACCAGCAGTCCAGCTTT 
PA GAAGTGCCATAGGCCAGGTTT CAACGCCTCATCTCCATTCC 
NA TGTTGATGGAGCAAACGGAGTA CTCAAACCCATGTCTGGAACTG 
HA GGCCCAACCACAACACAAAC AGCCCTCCTTCTCCGTCAGC 
IFNβ1 ATGACCAACAAGTGTCTCCTCC GGAATCCAAGCAAGTTGTAGCTC 
IFNα1 GCCTCGCCCTTTGCTTTACT CTGTGGGTCTCAGGGAGATCA 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
AC015849.2 AACTGTCAAGCTCAATTTCCCTCT GTGGAAAGGTTCGCTGGGAC 
TAPSAR1 GGAAAGACATCGGACCGTCA TGGGAAACGTTGGTGTCCTT 
RP1-71H24.1 TTCCAGCTGTCTCCTAATTTCC CTTTGTCCTGGTTGTCTTCCT 
CTD-2639E6.9 AAGTCTGACTCCAGTCCCCG GTTTGCGCTGCGAGATAAGG 
PSORS1C3 CATCATGGCACACAACAACC CCGGTCTAGGAAACCACTTATT 
AC007283.5 GTACTTTGGGAGGCTGAGTG CTGAAGTGCAGTGGTGTGA 
RP11-670E13.5 AAATAGCATTTTGTACCCGCACT GCCCGATTCCTCTTAGAAGGTT 
OAS1 CCGGCGATTTAACTGATCCTG TGTCCAAGGTGGTAAAGGGTG 
OAS2 AGGTGGCTCCTATGGACGG TTTATCGAGGATGTCACGTTGG 
IL6 GGTACATCCTCGACGGCATCT GTGCCTCTTTGCTGCTTTCAC 
IP10 GTGGCATTCAAGGAGTACCTC TGATGGCCTTCGATTCTGGATT 
TLR7 TCCTTGGGGCTAGATGGTTTC TCCACGATCACATGGTTCTTTG 
ISG56 GCCATTTTCTTTGCTTCCCCTA TGCCCTTTTGTAGCCTCCTTG 
β-actin GCCGGGACCTGACTGACTAC TTCTCCTTAATGTCACGCACGAT 
18S rRNA CGTTGATTAAGTCCCTGCCCTT TCAAGTTCGACCGTCTTCTCAG 
UGGT2 CCTTCGCAATCTTGGGATCAA GCCGGATCAATAAACAGAACCA 
UBE2G2 ATCTACCCTGATGGGAGAGTCT CTCCACTTTCGTCATTGGGC 
GANAB TGGGGATTACCCTTGCTGTG CCGTATGCTTCTCTGTCGCT 
BAG2 ATCAACGCTAAAGCCAACGAG CGTCACTGATCTGCCTCATGT 
SIL1 CTGCCTTCATCTAGGATGGCT GGGTTGGTCAGGGCAAACTC 
EIF2AK1 ACCCCGAATATGACGAATCTGA CAAGTGCTCCAGCAAAGAAAC 
UBE4B CTACCTCCCCAATAGGTGCAT GGCGAGCTGCTGAGAGAAC 
TAP1 GGATTCTACAAGATGGCTCAG TGTTGTTATAGATCCCGTCAC 
snU2RNA CATCGCTTCTCGGCCTTTTG TGGAGGTACTGCAATACCAGG 
PSMB8 CACGCTCGCCTTCAAGTTC AGGCACTAATGTAGGACCCAG 
M2 CGAGGTCGAAACGCCTATCAGAAAC CCAATGATATTTGCTGCAATGACGAG 
NS1 CCGACATGACTCTTGAGGAAAT CGCCTGGTCCATTCTGATAC 




2.9 Animal Studies 
Eight-week-old female C57BL/6J mice were infected with 1,000 pfu for a lethal 
challenge or 100 pfu for a sublethal challenge of influenza A virus (A/PR/8/34) in 50 µl volume 
via an intranasal route. Mice were treated by intraperitoneal injection of iCRT14 (50 mg/kg body 
weight) or DMSO as a vehicle control (4.2%) in a volume of 800 µl one day before virus 
infection and then daily from day 2 to day 5 as indicated. Mice were monitored for clinical 
symptoms such as arching back, huddling and ruffled fur. Body weight loss was monitored daily 
and mice which lost more than 30% body weight were euthanized and recorded as moribund and 
euthanized. For sublethal studies, clinical signs were scored as previously described (56): normal 
= 0, ruffled fur = 1, inactive = 3, hunched back and moribund = 4.  Mice were sacrificed at day 2 
and day 5 after infection. Left lungs were fixed in 10% neutral buffered formalin (Thermo 
Scientific, West Palm Beach, FL) and right lungs were snap-frozen in liquid nitrogen and used for 
RNA, protein and virus titer determination. For virus titer determination of lung tissues, right 
cranial lung lobes from infected mice were homogenized in 10% w/v phosphate-buffered saline 
(PBS) and were used for TCID50 assay. 
In a separate experiment, right lungs were used for collection of broncheoalveolar lavage 
(BAL) and left lungs were used for wet and dry ratio. Right lungs were lavaged with 500 µl ice 
cold PBS two time and approximately 80% volume was recovered. The BAL cells were spun 
down, resuspended and cytospin to slides. The slides were stained with dip quick stain (Jorvet, 
Loveland, CO). Differential cells counts were made with ≥ 400 cells per sample. The BAL fluid 
was frozen until use.   
 
2.10 Lactate dehydrogenase (LDH) assay and total protein measurement 
Lavage from the right lung lobe from each mouse of each group was used for LDH assay 
and total protein measurement. Fifty µls aliquots were used to measure the activity of LDH by 




lactate using a Thermo Scientific (Rockford, IL) LDH assay kit. Total protein in the BAL fluid 
was estimated by a modified Bradford assay according to the manufacturer's instructions 
(Biorad), and the remainder was frozen at −80 °C until processed.  
 
2.11 Histopathologic analyses 
Animals were euthanized by exsanguinations of abdominal aorta under Xylazine and 
Ketamine anesthesia as per approved IACUC protocol.  Formaline-perfused lungs were 
embedded in paraffin wax. Sections of 4 µm thickness were cut and stained with hematoxylin and 
eosin (H&E). Histopathologic lesions were scored by a board certified pathologist as described 
(57): 1 = minimal damage to alveolar structures, 2 = mild, 3 = moderate and 4 = marked/severe 
damage to lung tissue. 
   
2.12 RNA sequencing and data analysis 
A549 cells were infected with PR/8 at a MOI of 2 for 24 h. Total RNAs from 3 control 
and 3 infected cells were extracted. RNA-seq was performed by Applied Biological Materials, 
Inc. (Richmond, BC, Canada). RNA quality check was performed using the Agilent 2100 
Bioanalyzer. All samples were subjected to polyA enrichment, followed by first and second 
strand synthesis, adenylation of 3’ ends, adapter ligation, DNA fragment enrichment, and real-
time PCR quantification. Up to twenty-five million paired-end reads for each sample were 
generated. Paired-end reads were directionally mapped to the genomic loci of lncRNA (GRCh37 
/hg19) by TopHat2. CuffDiff analysis was then run to identify the dysregulated lncRNAs. Gene 
ontology (GO) functional annotation of mRNA expression profile was conducted by STIRNG 
analysis (http://string-db.org/). KEGG pathway enrichment in the altered mRNAs was also 
performed by STIRNG analysis. STRING is a web-based tool to investigate protein-protein 




2.13 Interferon treatment and lncRNA induction 
A549 cells were seeded in 12-well plates and cultured overnight. Cells were then treated 
with 1,000 U/ml human IFNβ1a (#11415-1, PBL assay science, Piscataway Township, NJ) in 
F12-K medium with 10% FBS and 1% PS for different times as indicated. At each time point, 
RNA was extracted for real-time PCR analysis. 
 
2.14 Lentiviral shRNA vector construction  
Lentiviral shRNA were constructed as previously describes (58). LncRNA-specific 
shRNA oligos (Table 2) were designed using BLOCK-iT™ shRNA Designer by Thermo Fischer 
Scientific (Grand Island, NY). The lentiviral vector that contained an irrelevant sequence was 
used as a negative control. For each lncRNA 3 different oligos were designed and shRNA vectors 
were prepared. Briefly, the oligos were annealed and ligated into the pSIH-H-copGFP vector 
(System Biosciences, Mountain View, CA) digested with BamH and EcoR1 restriction enzymes. 
These plasmids were transformed into STBL 3 cells and two colonies for each pair of oligos were 
selected from LB agar after overnight incubation. Colonies were propagated in LB broth 
overnight, plasmids were isolated and sequenced. Sequence confirmed designs were used for 













Table 2. Oligos used for constructing lncRNA shRNAs 
 










RPI-71H24.1- RE1 AATTCAAAAAGCTTCCAGCTGTCTCCTAATTTCTCTTGAAAATTAGGAGACAGCTGGAAGCG 
RPI-71H24.1- FW2 GATCCGGAAGACAACCAGGACAAAGATTCAAGAGATCTTTGTCCTGGTTGTCTTCCTTTTTG 
RPI-71H24.1- RE2 AATTCAAAAAGGAAGACAACCAGGACAAAGATCTCTTGAATCTTTGTCCTGGTTGTCTTCCG 
RPI-71H24.1- FW3 GATCCGGCAAGACTGCAACAGTATTGTTCAAGAGACAATACTGTTGCAGTCTTGCCTTTTTG 
RPI-71H24.1- RE3 AATTCAAAAAGGCAAGACTGCAACAGTATTGTCTCTTGAACAATACTGTTGCAGTCTTGCCG 
CTD-2639E6.9- FW1 GATCCGGATCCGGAGACTCCTTATCTTTCAAGAGAAGATAAGGAGTCTCCGGATCCTTTTTG 
CTD-2639E6.9- RE1 AATTCAAAAAGGATCCGGAGACTCCTTATCTTCTCTTGAAAGATAAGGAGTCTCCGGATCCG 
CTD-2639E6.9- FW2 GATCCGCAACACTCCATCTTCCAGAGTTCAAGAGACTCTGGAAGATGGAGTGTTGCTTTTTG 
CTD-2639E6.9- RE2 AATTCAAAAAGCAACACTCCATCTTCCAGAGTCTCTTGAACTCTGGAAGATGGAGTGTTGCG 
CTD-2639E6.9- FW3 GATCCGCAAACCTCAGGCAACTACAGTTCAAGAGACTGTAGTTGCCTGAGGTTTGCTTTTTG 
CTD-2639E6.9- RE3 AATTCAAAAAGCAAACCTCAGGCAACTACAGTCTCTTGAACTGTAGTTGCCTGAGGTTTGCG 
PSORS1C3- FW1 GATCCGGTCGAGAGCAAGTCTCTATTTTCAAGAGAAATAGAGACTTGCTCTCGACCTTTTTG 
PSORS1C3- RE1 AATTCAAAAAGGTCGAGAGCAAGTCTCTATTTCTCTTGAAAATAGAGACTTGCTCTCGACCG 
PSORS1C3- FW2 GATCCGAGCATCATGGCACACAACAATTCAAGAGATTGTTGTGTGCCATGATGCTCTTTTTG 
PSORS1C3- RE2 AATTCAAAAAGAGCATCATGGCACACAACAATCTCTTGAATTGTTGTGTGCCATGATGCTCG 
PSORS1C3- FW3 GATCCGTCGAGAGCAAGTCTCTATTGTTCAAGAGACAATAGAGACTTGCTCTCGACTTTTTG 
PSORS1C3-RE3 AATTCAAAAAGTCGAGAGCAAGTCTCTATTGTCTCTTGAACAATAGAGACTTGCTCTCGACG 
RP11-670E13.5- FW1 GATCCGCCCACAACACAATCACTCTCTTCAAGAGAGAGAGTGATTGTGTTGTGGGCTTTTTG 
RP11-670E13.5- RE1 AATTCAAAAAGCCCACAACACAATCACTCTCTCTCTTGAAGAGAGTGATTGTGTTGTGGGCG 
RP11-670E13.5- FW2 GATCCGCCTCAGTAAAGTCCACCCTGTTCAAGAGACAGGGTGGACTTTACTGAGGCTTTTTG 
RP11-670E13.5- RE2 AATTCAAAAAGCCTCAGTAAAGTCCACCCTGTCTCTTGAACAGGGTGGACTTTACTGAGGCG 
 
 
2.15 Lentivirus preparation and infection  
Lentivirus particles were produced in HEK293T cells using Lenti-X HTX Packaging Mix 




transfected with 3 μg of packing plasmids and 3 μg of lentiviral shRNA plasmid using 
Lipofectamine 2000 (Life Technologies).  Fresh DMEM media containing 10% FBS was added 
24 h after transfection. The cell culture supernatant was collected after a 48 h culture and 
centrifuged at 100 g for 10 min. The supernatant containing the lentivirus was aliquoted and 
stored at -80 ºC for future use. The viral titers were determined by infected HEK293T cells with a 
series of 10-fold dilutions of viral stock in the presence of 4 μg/ml of polybrene. The medium was 
changed after 24 h infection and GFP-positive cells were counted after additional 48 h culture. 
Virus titer was calculated determined based on this formula, infectious particle/ml = (Average of 
GFP positive cells from 10 random fields*594)/ (dilution factor*volume of infection) where 594 
is fields/well (20X objective) in a 12 well plate. 
For knockdown experiments, A549 cells were infected with a shRNA lentivirus in the 
presence of 4 μg/ml of polybrene at a MOI of 100 for 48 h. The infection efficiency was 
monitored by green fluorescent protein under a fluorescent microscopy. The knockdown 
efficiency of lncRNAs was determined by real-time PCR. 
 
2.16 Western blot analysis 
Cells were lysed in M-PER™ Mammalian Protein Extraction Reagent (Thermo Fischer, 
Waltham, MA). Proteins (30 µg/lane) were separated by 12% of SDS-PAGE and transferred onto 
nitrocellulose membranes using Trans-Blot® Turbo™ Transfer System (Bio-Rad, Hercules, CA). 
Membranes were blocked with 5% non-fat milk and then probed with different primary 
antibodies prepared in 5% non-fat milk overnight. Membranes were washed with TRIS-buffered 
saline for 5 min × 3 times and incubated with species-appropriate horseradish peroxidase-labeled 
secondary antibody for 1 h at room temperature. Membranes were again washed with TRIS-
buffered saline for 5 min × 3 times. Finally, the membranes were developed using SuperSignal™ 
West Pico Chemiluminescent Substrate (Thermo Fischer, Waltham, MA). Protein bands were 




Protein levels were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
quantitation was determined using Image Quant software from GE healthcare system. The 
primary antibody against GAPDH (cat# G8795) was purchased from Sigma-Aldrich (St. Louis, 
MO). Influenza viral protein antibodies, NP (cat# MCA400), NS1 (cat# SC-130568), and M2 
(cat# MA1-082) were purchased from AbD serotech (Raleigh, NC), Santa-Cruz biotechnology 
(Paso Robles, CA) and Thermo Fischer (Waltham, MA), respectively. Antibody dilutions were 
1∶2,000 for GAPDH, 1∶500 for NP, 1∶1,000 for NS1, and 1∶5,000 for M2. HRP-conjugated 
secondary antibodies against mouse (cat#115-0.5-003) and rabbit (cat#111-035-003) were 
purchase from Jackson Immuno Research (West Grove, PA) and used at a dilution of 1: 2,000 
and 1: 10,000 respectively.  
 
2.17 Isolation of cytoplasmic and nuclear RNAs 
Cytoplasmic and nuclear fractions were prepared from A549 cells using a kit (#21000, 
Norgen, Canada). cDNA was prepared using 1 µg RNA and real-time PCR was performed to 
analyze both cellular fractions using primers for β-actin, GAPDH, TAPSAR1 and U2snRNA. The 
expression of mRNA or lncRNA in nucleus and cytoplasm was calculated with the equation 2−Ct.  
The percentage of each RNA in the nucleus and cytoplasm were calculated. 
 
2.18 Data analysis 
Data from at least three independent experiments was analyzed. The results were 
statistically analyzed using Student's t-test or One-way ANOVA, followed by Tukey’s post hoc 









3.1 Activation of Wnt/β-catenin signaling increases influenza virus replication  
 To examine whether Wnt/β-catenin signaling affects influenza virus replication, we 
determined the effects of activation of the Wnt/β-catenin signaling using Wnt3a_CM on influenza 
viral gene expression. Mouse lung epithelial cells, E10 were pretreated with Wnt3a_CM and then 
infected with A/PR/8/34 for 18 h. Wnt3a_CM increased mRNA expression of the viral genes 
hemagglutinin (HA), M1 matrix protein (MP) and nucleoprotein (NP) (Fig. 3.1A). When mice 
were pre-treated with Wnt3a_CM and then infected with A/PR/8/34, increases in mRNA levels of 
HA, MP and NP in the lungs were also observed (Fig. 3.1B). These results indicate that Wnt3a 





Figure 3.1 Wnt3a increases influenza viral gene expression. (A) E10 cells were pretreated 
with 50% Wnt3a_CM or Con_CM for 24 h and infected with influenza virus A/PR/8/34 at a MOI 
of 1 for 18 h. (B) Mice were instilled with 10x Wnt3a_CM or Con_CM followed by PR/8 
infection (250 pfu/mice) and the lungs were collected on day 5 post infection. Relative mRNA 
expression levels of viral genes (HA, NP and MP) were measured by real-time PCR and 
normalized to GAPDH. Data is normalized to blank control and represented as mean ± SE (n = 
4). p < 0.05 vs. Con_CM (Students t-test). 
 
3.2 iCRT14 inhibits influenza virus infection. 
We next examined the effect of inhibiting Wnt/β-catenin signaling on influenza virus 
infection. iCRT14 is a small molecule that inhibits Wnt/β-catenin signaling by preventing the 
binding of β-catenin with LEF/TCF transcription factor (16, 27) and was used for this study. 
Human alveolar epithelial cells (A549) were treated with 12.5 µM iCRT14 for 12 h and then 
infected with A/PR/8/34 at a MOI of 1 for different times. Infectious virus particles released into 
the medium were quantified using a TCID50 assay. Virus titers in the iCRT14-treated cells were 




Similar results were observed with A/WSN/33 virus (Fig. 3.2B). This effect was not due to the 
toxicity of iCRT14 because iCRT14 had no effects on cell viability (Fig. 3.2C). These results 
indicate that iCRT14 has antiviral activity against different strains of influenza A virus.  
 
Figure 3.2. iCRT14 reduces influenza virus infection. (A, B) A549 cells were treated with 
iCRT14 (12.5 µM) or vehicle control for 12 h and then infected with A/PR/8/34 (A) or 
A/WSN/33 (B) at a MOI of 1. Media were collected at different times post infection and titers 
were determined by TCID50 assay. (C) A549 cells were treated with iCRT14 (12.5 µM) or vehicle 
control for various times and cell viability was measured by CellTiter Glo kit (Promega).  Results 
of 3 independent experiments are displayed as mean ± SE. *P<0.05 vs. vehicle control at the 














3.3 iCRT14 acts on the early stage of the influenza virus life cycle 
Influenza virus undergoes several steps of its life cycle in the host cell from entry to 
budding (59). To determine which stage of the viral life cycle was inhibited by iCRT14, we added 
the inhibitor at different times before and after infection and determined virus titers in the media 
at 12 hpi. When it was added 1 h before and up to 5 hpi, iCRT14 decreased virus titers (Fig. 3.3). 
However, iCRT14 had no effects on virus titers when it was added at 7 and 9 hpi. The result 
indicates that iCRT14 acts at the earlier stages at or before virus gene transcription.  
 
Figure 3.3 Effect of iCRT14 on stages of the influenza virus life cycle. A549 cells were 
infected with A/PR/8/34 at a MOI of 1. Cells were treated with iCRT14 (12.5 µM) or vehicle 
control at different times before or after infection. Media were collected 12 h post infection and 
titers were determined by TCID50 assay. Results of 3 independent experiments are displayed as 











3.4 iCRT14 reduces influenza virus RNA synthesis 
The influenza virions contain negative sense RNA (vRNA). The RNA synthesis of 
influenza virus occurs in three steps: (i) vRNA is transcribed into mRNA by cap snatching 
mechanism via RNA-dependent RNA polymerase enzyme, (ii) intermediate cRNA is synthesized 
from vRNA, and (iii) cRNA is copied to full length negative sense vRNA for new progeny virus 
particles (55, 60).  We further examined the effect of iCRT14 on the expression level of different 
types of influenza viral RNAs. A549 cells were treated with iCRT14 (12.5 µM) 1 h before 
infection and infected with A/PR/8/34 at a MOI of 5 for 5 h and cRNA, vRNA, and mRNA were 
measured with Real-time PCR. Ribavirin inhibits influenza virus RNA synthesis by inhibiting the 
polymerase complex (61) and was used as a positive control for this experiment. Similar to 
ribavirin, iCRT14 markedly reduced the levels of vRNA, cRNA and mRNA of all 8 segments 
including polymerase basic 1 (PB1), polymerase basic 2 (PB2), polymerase acidic (PA), HA, 
nucleoprotein (NP), NA, MP and non-structural protein (NS) (Fig. 3.4A, B, C). This effect was 











Figure 3.4 iCRT14 effect on influenza virus RNA synthesis. A549 cells were infected with 
A/PR/8/34 at a MOI of 5. Cells were treated with iCRT14 at 12.5 µM (A, B, C) or at indicated 
concentrations (D, E) at 1 h before infection. RNA was extracted at 5 h post infection. mRNA, 
cRNA, and vRNA levels of viral genes were determined by real-time PCR and normalized to 
GAPDH. Data was expressed as a percentage of vehicle control. Results of 3 independent 
experiments were displayed as mean ± SE. *P<0.05 vs. vehicle control, **P<0.01 vs. vehicle 









3.5 Antiviral activity of iCRT14 is independent of interferon production 
Interferons (IFNs) are the first line of defense against influenza virus. Influenza virus 
infection induces IFN production that is required for mounting a proper antiviral response (62). 
We designed two sets of experiments to test whether IFNs are involved in the antiviral activity of 
iCRT14. First, we examined the effects of iCRT14 on A/PR/8/34-induced IFN gene expression. 
A/PR/8/34 induced the mRNA expression of IFNα1 and IFNβ1 in A549 cells. However, iCRT14 
had no effect on this induction (Fig. 3.5A, B). Second, we repeated the experiment described in 
fig. 3.4 using Vero cells, which are deficient in IFN production (63, 64). Nevertheless, iCRT14 
reduced the levels of vRNA, cRNA and mRNA of the NP gene in Vero cells as it did in A549 
cells (Fig. 3.5C). These results suggest that the antiviral activity of iCRT14 is independent of the 
IFN response. 
 
Figure 3.5 iCRT14-mediated inhibition of influenza virus RNA synthesis is independent of 
the IFN response. (A, B) A549 cells were infected with A/PR/8/34 at a MOI of 1 for different 
times. Cells were treated with iCRT14 (12.5 µM) or vehicle control 1 h before infection. IFN α1 
and β1 mRNA levels were determined by real-time PCR and normalized to GAPDH. Data was 
expressed as fold change over mock infection. (C) Vero cells were infected with A/PR/8/34 at a 
MOI of 5. Cells were treated with iCRT14 (12.5 µM) or vehicle control 1 h before infection. 
cRNA, vRNA and mRNA levels of NP gene were determined at 5 h post infection using real-time 
PCR and normalized to GAPDH. Data is expressed as a percentage of vehicle control. Results of 





3.6 iCRT14 reduces influenza virus infection in primary alveolar epithelial cells 
AECs are one of the primary targets of influenza virus. We examined if iCRT14 also 
reduces influenza virus infection in primary AECs. AEC II were isolated from mice and cultured 
for 6 days to allow them to differentiate into AEC I (53, 65, 66). The day 6 cells showed a 
uniform staining of the AEC type I marker T1α (Fig. 3.6A). We treated these cells with iCRT14 
or vehicle and infected with A/PR/8/34 or A/WSN/33 at a MOI of 1 for 24 h and measured virus 
titers in the media and NA mRNA in the cells. We found that iCRT14 reduced virus titers (Fig. 
3.6B, C) and NA mRNA levels (Fig. 3.6D, E) in both A/PR/8/34 and A/WSN/33 infected cells. 
Our results indicate that iCRT14 is also effective in repressing influenza virus infection in 










Figure 3.6. Effect of iCRT14 on influenza virus infection in primary mouse alveolar 
epithelial cells (AECs). Mouse AECs were isolated from mice and cultured for 6 days. (A) AECs 
were immuno-stained with AEC type I maker, T1α and nuclear dye, DAPI. Scale bar = 50 µm. 
(B-E) AECs were infected with A/PR/8/34 or A/WSN/33 at a MOI of 1 for 24 h. Cells were 
treated with iCRT14 (12.5 µM) or vehicle control 1 h before infection. Titers in media were 
determined using TCID50 assay (B, C). NP mRNA levels in cells were determined by real-time 
PCR and normalized to GAPDH. Results of 3 independent experiments are displayed as mean ± 







3.7 iCRT14 partially protects mice from a lethal dose of influenza virus challenge 
To test whether iCRT14 protected mice from influenza virus infection, we performed a 
survival study with a lethal dose of influenza virus A/PR/8/34 (1,000 pfu/mouse). Mice were 
treated with iCRT14 (50 mg/kg body weight) one day before infection and daily thereafter until 
day 6 after infection. The dose was chosen based on reports from other groups for tumor studies 
(16, 67). The results showed that iCRT14-treated mice exhibited a slightly less body weight loss 
at day 8 (Fig. 3.7A) and a slight improvement in survival time (Fig. 3.7B).  
 
Figure 3.7 Effects of iCRT14 on weight loss and survival rate in mice challenged with a 
lethal dose of A/PR/8/34. C57BL/6J mice were treated with iCRT14 (50 mg/kg) or vehicle 
control one day before infection daily until day 6 post infection. The mice were challenged with 
A/PR/8/34 (1,000 pfu/mouse). (A) Percent of body weight loss. Body weight loss is presented as 
mean ± SE. *p < 0.05 vs. vehicle control at day 8 (Student t-test). (B) Kaplan–Meier survival 
curves of iCRT14 and vehicle control groups. Mantel-Cox χ2 test was used for analysis *P< 0.05, 







3.8 iCRT14 attenuates clinical signs associated with a sublethal dose of influenza virus 
challenge 
In our survival study, 30% body weight loss necessitated euthanasia. However, human 
patients with flu infection normally do not lose that much body weight (8). Thirty percent weight 
loss in mice corresponds to human patients with severe acute respiratory distress syndrome 
caused by influenza virus (68, 69) and therefore survival study in mice does not necessarily 
mimic human disease conditions.  We thus performed a sublethal dose of A/PR/8/34 challenge 
(100 pfu/mouse) in mice and examined virus loads and lung pathology. Under these conditions, 
no mortality was observed in both control and iCRT14-treated groups. iCRT14 significantly 
reduced virus titers in the lung tissues at 2 and 5 days post infection (Fig. 3.8A). There was no 
difference in clinical scores at day 2 post infection between iCRT14-treated and control mice. 
However, at 5 days after infection, iCRT14-treated mice showed significant lower clinical scores 
compared to control mice (Fig. 3.8B).  The mice treated with iCRT14 had a decreased wet-to-dry 
ratio, an indicator of extravascular edema in lungs, at 5 days after infection (Fig. 3.8C).  
However, we did not observe differences in total protein, number of inflammatory cells 
(macrophages, neutrophils and lymphocytes) and LDH activity in BAL between iCRT14-treated 
and control groups (Fig. 3.8D, E, F), suggesting that iCRT14 does not improve alveolar leakage, 





Figure 3.8 Effect of iCRT14 on lung injury and inflammation of mice with a sub-lethal dose 
of A/PR/8/34 challenge. C57BL/6J mice were infected with A/PR/8/34 (100 pfu/mouse). Mice 
sacrificed on the day 0 of study were used as a control. Mice received either iCRT14 (50 mg/kg) 
or vehicle control daily beginning one day before infection until day 2 or day 5 after infection. 
(A) Virus titers in total lung homogenate (n=6). (B) Average clinical scores. 0 = Normal, 1 = 
Ruffled fur, 2 = Inactive, 3 = Hunched back (n = 10 – 20). (C) Lung water content as measured 
by wet-to-dry ratio. n = 4. (D) Total proteins in BAL fluid. n = 4. (E) LDH activity in BAL fluid 
n = 4. (F) Inflammatory cells in BAL. n = 3 – 4. All the data are presented as mean ± SE. *P < 
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3.9 Effect of iCRT14 on lung histopathology of mice with a sub-lethal dose of A/PR/8/34 
challenge. 
H & E staining revealed that at day 2 post infection iCRT14 equivocally reduced 
epithelial degeneration and/or necrosis in major airways when compared to vehicle control (Table 
3).  At day 5 post infection there was decrease attenuation of epithelium and loss of cilia with the 
treatment of iCRT14. There was subtle decrease in severity of the lung lesions such as alveolar 
histiocytic infiltration and neutrophilic and histiocytic infiltration in major airways in the 









Figure 3.9 histopathology of mice lungs with a sub-lethal dose of A/PR/8/34 challenge and 
treated with iCRT14. C57BL/6J mice were infected with A/PR/8/34 (100 pfu/mouse). Mice 
received either iCRT14 (50 mg/kg) or vehicle control daily beginning one day before infection 
until day 2 or day 5 after infection. Representative H&E photomicrographs from 6 mice are 
shown. A, B = day 2 vehicle control mice; C, D = day 2 iCRT14 mice; E, F = day 5 vehicle mice; 
G, H = day 5 iCRT14 mice. Dark arrowheads represent alveolar histiocytic and neutrophil 
infiltrations with associated hemorrhage in Panels A, C, E, G. Arrowheads represent major 
airway degeneration/necrosis, histiocytic and neutrophil infiltration in Panels B, D, F, H. Scale 
bar = 50 µm. 
Table 3: Histopathology of the lungs of mice infected with a sublethal dose of influenza 










3.10 iCRT14 toxicity 
Finally, we evaluated whether iCRT14 causes toxicity in mice. Mice were treated with 
iCRT14 at doses of 50 and 100 mg/kg or vehicle control every day for 9 days via intraperitoneal 
route. Major organs including liver, lung, heart, kidney, stomach, small intestine, eyes and brain 
were processed for histopathological analysis.  Microscopic lesions were scored by a pathologist. 
Major organ toxicity was not identified with iCRT14 treatment at either doses of iCRT14. 
 
3.11 LncRNAs are differentially expressed in influenza virus-infected A549 cells 
To identify lncRNAs that are dysregulated during influenza virus infection, we infected 
lung epithelial A549 cells with PR/8 at a MOI of 2 for 24 h and performed RNA-seq analysis. 
Tophat was used for read mapping and Cufflinks/Cuffdiff was used for gene expression 
quantification. Figure 3.10A depicts the design of the experiment. Using a p value of < 0.05, we 
found that 8,983 mRNAs were significantly changed by PR/8 infection (Fig. 3.10B). Of them, 
3,649 mRNAs were upregulated and 5,334 mRNAs were downregulated (Fig. 3.10C). 1,625 up-
regulated and 2,784 down-regulated mRNAs were changed 2-fold or more (Table 4). The 
numbers of mRNAs with various fold changes are also listed in Table 4. Up-regulation of ISGs 
was observed (Table 5), indicative of successful influenza virus infection.  
Similarly, we identified 1,912 lncRNAs that were significantly changed in PR/8-infected 
A549 cells (Fig. 3.10D). Of them, 716 lncRNAs were up-regulated and 1,196 lncRNAs were 
down-regulated (Fig. 3.10E). There were 418 up-regulated and 683 down-regulated lncRNAs 
based on a fold change of 2 or more.  Interestingly there were only 11 down-regulated lncRNAs 
compared to 68 up-regulated lncRNAs based on a fold change of > 100 (Table 4).  
Given a greater number of lncRNAs that are up-regulated compared to the down-
regulated lncRNAs during influenza virus infection based on a fold change of  > 100 (Table 4), 




selection, we used the following criteria: (a) a fold change of >2 for up-regulated lncRNAs, (b) 
significant changes in the expression of neighboring genes (up or down) within 10,000 kb of 
lncRNAs, (c) neighboring genes involved in > 5 pathways based on GO analysis, and (d) >500 
base pair long with no ORF (open reading frame). Seven lncRNAs met these criteria and are 
listed in Table 6 and marked in yellow color in the scatter plot (Fig. 3.10B). These lncRNAs were 
composed of different types of transcripts (Table 6). Four of them were anti-sense lncRNAs that 
overlap the genomic span of a protein-coding locus on the opposite strand. AC015849.2 has two 
neighboring genes, Chemokine (C-C Motif) Ligand 5 (CCL5) and TATA Box Binding Protein 
(TBP)-Associated Factor (TAF15). CCL5 was highly upregulated (147,688-fold), which is 
consistent with a previous report (70) whereas TAF15 was downregulated (5-fold).  The other 
two anti-sense lncRNAs RP-1-7H24.1 and RP11-670E13.5 have well-known antiviral genes, 
OAS2, OAS3 and TRIM25 as their neighbors (71). They were also highly upregulated (Table 6).  
The neighboring genes of TAPSAR1, an anti-sense lncRNA; PSMB8 and TAP1 were 
upregulated. Neighboring genes of intergenic lincRNA CTD-2639E6.9 were either 
downregulated (FTL) or not detected (BAX) by RNA-seq. AC007283.5 is 3 prime overlapping 
lncRNA that overlaps the 3'-UTR of a protein-coding locus on the same strand and its 
neighboring genes, CASP10 and CFLAR were upregulated. PSOR1C3 is a sense intronic 
lncRNA that lies within introns and do not overlap with exons. Its neighboring genes, POU5F1 







Figure 3.10. lncRNAs are differentially regulated during influenza virus infection. (A) 
Flowchart of RNA-seq experiment design. (B, C) Volcano plot of differentially expressed 
mRNAs and lncRNAs in PR/8-infected A549 cells at MOI of 2 for 24 h. Downregulated genes 
are denoted in green color and upregulated genes in red color based on a p-value of ≤ 0.05 and a 
fold change of ≥ 2. Genes with a p-value of > 0.05 or a fold change of < 2 are marked with black 
color. The yellow colored lncRNAs are the selected lncRNAs for further analysis (see the text). 
(D, E) Pie charts of significantly changed mRNAs and lncRNAs with a p-value of ≤ 0.05. Green 








Table 4. Summary of RNA-seq data sets 
Fold change 
lncRNA mRNA 
Up-regulated Down-regulated Up-regulated Down-regulated 
> 100 68 11 80 0 
50-100 5 1 45 2 
10-50 71 59 238 79 
2-10 274 612 1,262 2,703 
 
Table 5. Interferon-stimulated antiviral genes 
Anti-viral genes 
Expression level (FPKM) 
Fold change 
Control Influenza virus 
OAS1 (2'-5'-Oligoadenylate Synthetase 1) 21 421 20 
OAS2 (2'-5'-Oligoadenylate Synthetase 2) 0.12 173 1,468 
OAS3 (2'-5'-Oligoadenylate Synthetase 3) 19 181 10 
OASL (2'-5'-Oligoadenylate Synthetase-Like) 0.46 1,539 3,327 
MX1(MX Dynamin-Like GTPase 1) 0.42 222 526 
ISG15 (ISG15 Ubiquitin-Like Modifier) 3 974 367 
ISG20 (Interferon Stimulated Exonuclease Gene) 6 251 41 
IRF1 (Interferon Regulatory Factor 1) 9 237 27 
IRF2 (Interferon Regulatory Factor 2) 9 27 3 
IRF7 (Interferon Regulatory Factor 7) 2 163 74 
IRF9 (Interferon Regulatory Factor 9) 39 164 4 


























change Con Flu Con Flu 




CCL5 0.02 2,988 147,688 
TAF15 219 44 - 5 




PSMB8 9 51 5 
TAP1 8 253 33 
RP1-
71H24.1 




OAS2 0.12 173 1,470 
OAS3 19 181 10 
CTD-
2639E6.9 




FTL 8,488 3,245 - 3 
BAX ND ND ND 






CASP10 2 14 6 
CFLAR 27 137 5 






POU5F1 2 22 13 
HLA-C 24 412 17 
RP11-
670E13.5 




TRIM25 27 199 7 
DGKE ND ND ND 
Fold changes: from RNA-seq data 
bp: length in terms of base pairs 
ND: Not detected by RNA-seq 
- number: Downregulation 
FPKM: Fragments Per Kilo base of transcript per Million mapped reads 
CCL5: Chemokine (C-C motif) ligand 5  
TAF15: TATA Box Binding Protein (TBP)-Associated Factor 
PSMB8: Proteasome Subunit Beta 8 
TAP1: Transporter 1, ATP-Binding Cassette 
OAS2: 2'-5'-Oligoadenylate Synthetase 2 
OAS3: 2'-5'-Oligoadenylate Synthetase 3 
FTL: Ferritin, Light Polypeptide 
BAX: BCL2-Associated X Protein 
CASP10: Caspase 10, Apoptosis-Related Cysteine Peptidase 
CFLAR: CASP8 and FADD-Like Apoptosis Regulator 
POU5F1: POU Class 5 Homeobox 1 
HLA-C: Major Histocompatibility Complex, Class I, C 
TRIM25: Tripartite Motif Containing 25 











3.12 Go pathway analysis of lncRNAs 
Because the functions of most lncRNAs are unknown and lncRNAs often regulate their 
neighboring genes (72) , we selected the genes within 10,000 kb of significantly changed 
lncRNAs during influenza virus infection for GO analysis including cellular components, 
molecular pathways and biological processes. Prediction terms with a p-value of less than 0.05 
were selected and ranked. Enrichment scores (−log10(p-value) were plotted on x-axis. The most 
enriched cellular components were related to endosome (Fig. 3.11A). The genes involved in the 
α, β, and γ IFN and immune signaling or cellular responses are enriched in the molecular and 
biological pathways (Fig. 3.11B, C). The GO analysis revealed the neighboring genes of the 
lncRNAs changed by influenza virus were enriched in the pathways and processes that are known 












Figure 3.11. GO pathway analysis of lncRNA co-expressed mRNAs.  Protein-coding genes 
within 10,000 kb distance of the significantly dysregulated lncRNAs during influenza virus 
infection were selected for GO analysis. GO analysis includes 3 annotations- cellular components 













3.13 Validation of RNA-seq results with qPCR 
We then utilized real-time PCR to validate the results from RNA-seq analysis using the 
same RNAs from the RNA-seq analysis. Real-time PCR confirmed that all of the 7 lncRNAs 
were induced by PR/8 (Fig. 3.12A) although the absolute fold changes varied between real-time 
PCR and RNA-seq for some lncRNAs (Fig. 3.12C). For the mRNA real-time PCR validation, we 
selected the genes that are implicated in endoplasmic reticulum (ER) stress since ER stress is 
involved in viral replication and vice-versa (73, 74). The genes that were included for this 
analysis were UDP-Glucose Glycoprotein Glucosyltransferase 2 (UGGT2), Ubiquitin-
Conjugating Enzyme E2G 2 (UBE2G2), Glucosidase, Alpha; Neutral AB (GANAB), BCL2-
Associated Athanogene 2 (BAG2), SIL1 Nucleotide Exchange Factor (SIL1), Eukaryotic 
translation initiation factor 2-alpha kinase 1 (ELF2AK1) and Ubiquitination Factor E4B 
(UBE4B). All of the genes were down-regulated and similar changes were observed using real-

















Figure 3.12. Real-time PCR confirmation of RNA-seq results. (A, B) Relative expression of 
selected lncRNAs and mRNAs performed on the same samples as for RNA-seq using real-time 
PCR. Data was normalized to β-actin and expressed as means ± SE. n = 3 independent 
experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. control (paired student’s t-test). (C, D) 








3.14 Effects of influenza virus strains on lncRNA expression 
Influenza A virus strains exhibit different virulence for a particular host (75). We thus 
examined if the up-regulated lncRNAs by PR/8 are also induced by other strains of influenza 
viruses. We found that lncRNA induction by PR/8 is dose-dependent (Fig. 3.13). RP1-7H24.1, 
TAPSAR1, and RP11-670E13.5 expression reached maximum at a MOI of 0.2 while 
AC015849.2, CTD-2639E6.9, AC007283.5, and PSORS1C3 had a highest expression at a MOI 
of 2. We then compared the effects of 3 influenza A virus strains on the lncRNA expression using 
a MOI of 2 in A549 cells: PR/8, WSN and Pdm/OK. WSN and Pdm/Ok are another commonly 
used laboratory strain and a clinical isolate of 2009 Oklahoma pandemic influenza H1N1 virus of 
swine origin, respectively. All of the seven lncRNAs were induced by all the strains except that 
Pdm/OK had no effects on PSORS1C3 expression and that Pdm/Ok-induced RP11-670E13.5 
expressions did not reach a significant level due to the variation between the experiments (Fig. 
3.13). However, the magnitude of induction varied among strains and lncRNAs. Similar 
inductions were observed for TAPSAR1 by 3 strains. WSN induced much higher expression of 
AC015849.2, CTD-2639E6.9 and PSORS1C3 compared to PR/8 and Pdm/OK while PR/8 and 
Pdm/OK increased RP1-7H24.1expression more than WSN. PR/8 and WSN were more effective 
in the induction of AC007283.5 than Pdm/OK. Finally, PR/8 induced a higher expression of 















Figure 3.13. lncRNA induction by different influenza viruses. A549 cells were infected with 
influenza A viruses, PR/8 (MOI: 0.02, 0.2 and 2), WSN (MOI 2) and Pdm/OK (MOI 2) for 24 h. 
lncRNA expression levels were determined by real-time PCR and normalized to β-actin. Results 
are represented as means ± SE from three independent experiments. *p < 0.05, **p < 0.01 and 








3.15 lncRNAs are induced by IFNβ1 
Influenza viruses are known to induce IFN response. Hence, we examined whether type I 
IFN induce the expression of lncRNAs identified above. We treated A549 cells with 1,000 U/ml 
IFNβ1 for different times (0, 3, 9 and 24 h) and determined the expression levels of lncRNAs by 
real-time PCR. IFNβ1 treatment markedly increased the expression of OAS1, a known ISG gene 
(76) (Fig. 3.14). We found that 6 of the 7 lncRNAs were significantly induced by IFNβ1. 
PSORS1C3 level was also increased by IFNβ1, but did not reach a significant level. The IFNβ1-
induced expression of lncRNAs occurred as early as 3 h post treatment and reached a maximum 





Figure 3.14 Effect of IFNβ1 on lncRNA expression. A549 cells were treated with IFNβ1a 
(1,000 U/ml) for different times.  Interferon inducible gene, OAS1 and lncRNA levels All 7 were 
determined by real-time PCR and normalized to18S rRNA. Fold change was calculated based on 
0 h and results are represented as means ± SE from three independent experiments. *p < 0.05, and 





3.16 Knockdown of lncRNAs using lentivirus shRNAs  
To determine the functional roles of the identified lncRNAs on influenza virus replication 
we attempted to knockdown lncRNAs using lentivirus-based shRNAs. The expression levels of 
TAPSAR1, CTD-2639E6.9, and PSORS1C3 were reduced by 52.07 ± 0.92, 48.06 ± 2.73 and 












Figure 3.15. Knockdown efficiency of lncRNA shRNAs. A549 cells were infected with a 
lentiviral lncRNA shRNA or its control (shRNA-Con) at a MOI of 100 for 48 h, followed by 
PR/8 infection at a MOI of 2 for 24 h. LncRNA shRNA infection efficiency was monitored by 
GFP (A) and representative images of shRNA-con were shown in A (Scale bar = 50 µm). 
LncRNA knockdown (B) efficiency was measured by real-time PCR and β-actin was used as a 
housekeeping control. Fold change was calculated based on shRNA-con. Results are represented 







3.17 Knockdown of TAPSAR1 reduces influenza virus replication  
We then determined the effects of TAPSAR1, CTD-2639E6.9 and PSORS1C3 
knockdown on influenza virus replication. The virus titer in the culture medium of TAPSAR1 
shRNA-1-treated cells was reduced 10-fold compared to shRNA-control (Fig. 3.16). We did not 
observe significant reduction in the virus titer with knockdown of other two lncRNAs CTD-
2639E6.9 and PSORS1C3 with the shRNAs which were able to knockdown respective lncRNA 




Figure 3.16 Effect of lncRNA knockdown on influenza virus replication. A549 cells were 
infected with lentiviral shRNA-Con or shRNA against TAPSAR1, CTD-2639E6.9 and 
PSORS1C3 at a MOI of 100 for 48 h, followed by PR/8 infection at a MOI of 2 for 24 h. 
Influenza virus particles in culture media were determined by TCID50 assay in MDCK cells. 
Results are expressed as TCID50/ml and represented as means ± SE from three independent 








3.18 TAPSAR1 knockdown results in reduced influenza viral protein synthesis and mRNA. 
We further investigated the effects of TAPSAR1 knockdown on influenza viral mRNA 
and protein levels in single-cycle and multi-cycle infections. We knocked down TAPSAR1 in 
A549 cells with TAPSAR1 shRNA-1 for 48 h and infected with PR/8 at MOI 2 for 8 h (single-
cycle) or MOI 0.2 for 24 h (multi-cycle). The reduction of TAPSAR1 levels were confirmed in 
both types of infection cycle settings (Fig. 3.17A). The knockdown of TAPSAR1 significantly 
reduced NS1 protein levels in both single-cycle and multi-cycle infections (Fig. 3.17B, C). Matrix 
protein 2 (M2) and nuclear protein (NP) were significantly decreased by TAPSAR1 knockdown 
in single-cycle and multi-cycle infections, respectively (Fig. 3.17B, D, E). TAPSAR1 shRNA2, 
which did not decrease the TAPSAR1 level, had no effects on influenza viral protein expression. 
The knockdown of TAPSAR1 had no effects on mRNA levels of NS1, M2 and NP in single-
cycle and multi-cycle infection except NP mRNA was moderately reduced in single-cycle 
infection (Fig. 3.18C). Taken together, these results indicate that TAPSAR1 knockdown mainly 

















Figure 3.17 Effect of TAPSAR1 knockdown on influenza virus protein synthesis. A549 cells 
were infected with lentiviral shRNA-Con or shRNA against TAPSAR1 at a MOI of 100 for 48 h, 
followed by PR/8 infection at a MOI of 2 for 8 h (single-cycle infection) or at a MOI of 0.2 for 24 
h (multi-cycle infection).   (A) TAPSAR1 expression levels were determined by real-time PCR 
and normalized to β-actin. (B-E) Influenza viral protein (NS1, M2 and NP) levels were measured 
by western blotting. The protein bands were quantitated using Image Quant software and 
normalized to GAPDH. All of the data are expressed as a fold change over respective shRNA-
Con and represented as means ± SE from 3 independent experiments. *p < 0.05 vs. respective 









Figure 3.18 Effects of TAPSAR1 knockdown on influenza virus mRNAs. A549 cells were 
infected with lentiviral shRNA-Con or shRNA against TAPSAR1 at a MOI of 100 for 48 h, 
followed by PR/8 infection at a MOI of 2 for 8 h (single-cycle infection) or at a MOI of 0.2 for 24 
h (multi-cycle infection).  mRNA levels of NS1 (A), M2 (B) and NP (C) were measured by real-
time PCR and normalized with β-actin. Data is represented as means ± SE from 3 independent 
















3.19 TAPSAR1 is localized in nucleus of A549 cells 
As the first step in elucidating mechanisms of TAPSAR1-mediated influenza virus 
replication, we determined the location of TAPSAR1 in cells. We isolated cytoplasmic and 
nuclear fractions from A549 cells and determined TAPSAR1 levels in both fractions using real-
time PCR. As shown in Fig. 3.19, TAPSAR1 was enriched in the nucleus similar to nuclear 




Figure 3.19. Location of TAPSAR1 in A549 cells. The levels of TAPSAR1, GAPDH and β-
actin mRNAs (cytoplasmic RNA positive controls), and U2snRNA (nuclear RNA positive 
control) in cytoplasmic and nuclear fractions of A549 cells were determined by real-time PCR. 









3.20 Knockdown of TAPSAR1 does not affect its neighboring gene PSMB8 
Human TAPSAR1 is located on chromosome 6p21.32 and overlapping with the antisense 
strand of TAP1 (Transporter 1, ATP-Binding Cassette, Sub-Family B protein) and PSMB8 
(Proteasome Subunit, Beta Type, 8) genes. TAP1 is involved in the transport of antigens from the 
cytoplasm to the endoplasmic reticulum for association with MHC class I molecule (77), whereas 
PSMB8 plays role in antigen processing to generate class I binding peptides (78). Because 
lncRNAs may function by regulating their neighboring genes, we evaluated mRNA expression of 
TAP1 and PSMB8 after the knockdown of TAPSAR1 in A549 cells. TAPSAR1 shRNA-1 
reduced the TAPSAR1 level by 52 % and TAPSAR1 shRNA-2 had no significant effects on 
TAPSAR1 expression (Fig. 3.15B). However, both TAPSAR1 shRNA-1 and shRNA-2 did not 
affect PSMB8 mRNA expression (Fig. 3.20). TAP1 mRNAs were not detectable in all the 
conditions. This result suggests that the effects of TAPSAR1 on influenza virus infection are 












Figure 3.20. Effects of TAPSAR1 knockdown on PSMB8 expression.  Real-time PCR analysis 
of PSMB8 mRNA in A549 cells infected with lentivirus for 48 h with shRNA-con, shRNA-1and 
shRNA-2 followed by PR/8 infection at MOI 2 for 24 h. A549 cells with (Blank) or without 
(Control) at same MOI of PR/8 served as controls. PSMB8 levels were measured by real-time 
PCR and normalized to β-actin.  Results are represented as mean ± SE from three independent 













3.21 TAPSAR1 knockdown results in the reduction of IP10 
To screen potential antiviral genes that are changed by TAPSAR1 knockdown, we 
performed real-time PCR for OAS1, OAS2, ISG56, TLR7, IL6 and IP10. TAPSAR1 knockdown 
had no effects on OAS1, OAS2, ISG56 and IL6 expression, but significantly reduced TLR7 and 
IP10 level (Fig. 3.21). 
 
 
Figure 3.21. Antiviral response gene profiles after TAPSAR1 knockdown. A549 cells were 
infected with lentiviral shRNA-Con or shRNA1 against TAPSAR1 at a MOI of 100 for 48 h, 
followed by PR/8 infection at a MOI of 2 for 8 h. Real-time PCR analysis of antiviral genes and 
inflammatory cytokines using 3 independent shRNA-Con and 3 shRNA1 samples.  The results 
were normalized to β-actin. Data is represented as means ± SE from three independent 









4.1 Influenza virus and host signaling pathways. 
In this study, we found that activation of Wnt/β-catenin with Wnt3a enhanced influenza 
virus replication and that inhibition of this pathway with iCRT14 decreased influenza virus 
transcription and production of new virus. iCRT14 acted at or before viral RNA synthesis and its 
effect was independent of IFN production. iCRT14 also showed a partial protective effect in a 
mouse model of influenza virus infection and may have potential for development as a 
therapeutic candidate against influenza virus.   
Various host signaling pathways are altered during influenza virus infection and thus 
these pathways can provide potential therapeutic targets. Cellular signaling pathways such as NF-
κB signaling, MAPK pathway, PI3K/Akt pathway, PKC/PKR signaling, and TLR/RIG-I 
signaling cascades have been reported to play role in various stages of the influenza virus 
replication cycle. NF-κB signaling is essential for the host innate immune response and is 
activated by influenza virus infection (79). Once it is activated, NF-κB signaling increases 
influenza virus production by inducing proapoptotic factors (80). Influenza virus also activates 
the MAPK pathway and blocking this signaling pathway inhibits virus replication by impairing 




the PI3K/Akt pathway via the interaction of NS1 and p85β (82). There is robust activation of 
interferon response during influenza virus infection, which in turn activates the PKR signaling 
pathway. However, influenza virus also counteracts activation of PKR pathway by the binding of 
NS1 to double stranded RNA, thereby preventing translational arrest (83). Pattern recognition 
receptors such as toll-like-receptors (TLR) and RIG-I like receptors (RLRs) recognize viral RNAs 
and induce antiviral immune responses (84). Influenza virus has also evolved mechanisms to 
counteract this induction of the antiviral response. For example, NS1 inhibits RIG-I activation 
and IFN production by binding TRIM25, an ubiquitin ligase that is required for RIG-I activation 
(85). 
4.2 Wnt signaling and influenza virus 
Our current study demonstrates that Wnt/β-catenin signaling enhances influenza virus 
replication as we showed that Wnt3a enhanced viral gene expression in PR8-infected mouse lung 
epithelial cells in cell culture and PR8-infected lungs in vivo. We also demonstrated that the 
Wnt/β-catenin inhibitor, iCRT14 inhibited virus replication and viral gene expression in H1N1 
A/PR/8/34- and A/WSN/33-infected human lung epithelial A549 cells and primary mouse 
alveolar epithelial cells. There are very limited studies on the effects of Wnt/β-catenin signaling 
on influenza virus infection. Using an RNAi approach, one study has reported that silencing of 
various components in Wnt/β-catenin signaling affects PR8 replication. However, the results are 
difficult to interpret since the deletion of these genes has either a positive or negative effect on 
PR8 replication (13). Another study has shown that the addition of Wnt3a or overexpression of β-
catenin inhibits H7N7 influenza virus replication (86), in contrast with our observation that 
Wnt3a actually enhances H1N1 viral gene expression.  The discrepancy is likely due to the 





4.3 iCRT14 and interferon response 
The inhibition of influenza virus replication by iCRT14 is not via the IFN response since 
iCRT14 maintained its ability to inhibit influenza virus replication in the IFN-deficient Vero cells 
and had no effects on the influenza virus-induced IFN response in A549 cells. Different effects of 
Wnt/β-catenin on IFN response during virus infection were reported. The Wnt ligand WNT2B 
and WNT9B negatively regulate the IFN response during Sendai virus infection (87) and deletion 
of WNT9B positively regulates the IFN response (13). In contrast, Wnt3a increases the IFN 
response in the absence of NS1 protein, which is the main protein that influenza virus uses to 
repress the host IFN response (13). The transfection of β-catenin and LEF-1 plasmids into A549 
cells also induces the ISRE gene reporter when treated with cellular or viral RNA (86).   
4.4 iCRT14 and in vivo studies 
In a xenograft model of BT-474 cells in SCID mice, iCRT14 treatment was shown to 
reduce tumor volume significantly (67). Mouse Ewing’s sarcoma in vivo was also inhibited by 
iCRT14 (88). However, there is a paucity of literature on the toxicity of iCRT14 in animals. Our 
10-day toxicity study in mice did not reveal any major toxicity in organs such as lung, liver, 
kidney, brain, heart and eyes. In a sub-lethal influenza infection mouse model, iCRT14-treated 
mice showed less severe clinical symptoms, which were correlated with the observation that those 
mice had lower virus loads (Fig. 3.8A). Influenza virus infection causes acute lung injury 
including damage to endothelial and epithelial cells, disruption of the endothelial alveolar barrier, 
leakage of proteins into the alveolar space, and inflammatory cell infiltration. However, iCRT14 
appears to have no effects on parameters of lung injury and inflammation except that it reduces 
lung edema. In a lethal influenza infection, we only observed slightly lower weight loss and 
delayed mortality in iCRT14-treated mice. These end points could be used to improve the 




and improved clinical symptoms, a combination therapy (89) with other drugs to reduce lung 
injury should increase efficacy of iCRT14.  
 
4.5 RNA-seq experiment 
Influenza virus requires host cellular factors to function as revealed by several high 
throughput and genome wide studies (90-92).  Since virus infection leads to global translation 
inhibition (93), a translation-independent system is needed to prepare cells for antiviral responses. 
lncRNAs represent a such potential class of host factors and are new alternatives for development 
of host-centric antiviral strategies. In this study we identified a lncRNA TAPSAR1 whose 
knockdown reduced influenza virus replication. TAPSAR1 was induced by different influenza 
virus strains and type I IFN. TAPSAR1 knockdown led to reduction in proinflammatory cytokine 
IP10.  
Our present studies showed that a large number of human lncRNAs (3,158), along with 
protein-coding genes (8,638), were differentially expressed after influenza virus infection. A 
recent microarray analysis reported a similar number of non-coding transcripts (3,415 and 3,401) 
altered by influenza virus infection using two commercial microarrays, NCode™ and Sureprint™ 
G3 (50). However, RNA-seq technique yields more comprehensive datasets of both lncRNA and 
mRNA along with less false-positive hits (94).  
It is well known that influenza virus hijacks cellular protein synthesis machinery (95) to 
make more viral proteins. It is conceivable that many of the cellular mRNAs are downregulated 
(96). Our RNA-seq datasets revealed a higher number of lncRNAs and mRNAs were up-
regulated than these that were down-regulated. Previous studies have shown that lncRNAs can 
regulate their neighboring genes (72). GO analysis using upstream and downstream protein 
coding genes within 10,000 kb distance of the dysregulated lncRNAs indicated that many of the 
lncRNAs were associated with pathogen-related immune signaling pathways and responses based 




component enrichment. This is consistent with the fact that influenza virus enters cells via 
endocytosis (97). Thus there is a correlation between influenza virus infection and the pathways 
and processes that are highly enriched for immune signaling and responses.  
 
4.6 LncRNAs and viruses 
Among 1,298 up-regulated lncRNAs in PR/8-infected cells, 7 selected lncRNAs in our 
studies were also induced by other H1N1 strains, WSN and Pdm/OK, but the magnitude of 
induction varied, indicating that there are differences in virus strains in induction of lncRNA 
expression. lncRNA expression can be induced by not only influenza viruses but also other RNA 
viruses including human immunodeficiency virus (HIV) (45) and hepatitis C virus (HCV) (49) 
and DNA viruses such as herpesviruses (46). Efforts have been made to understand if lncRNA 
induction is due to a direct viral effect or changes in host cellular signaling. One study has 
demonstrated that live influenza virus is necessary for induction of lncRNA VIN (50). Although 
it is induced by various strains of influenza virus such as H1N1, H3N2 and H7N7, VIN is not 
inducible by IFN or viral RNA mimics. On other hand, host IFN signaling also contribute to the 
induction of lncRNA expression as demonstrated by using IFNs (52, 98, 99) or NS1-mutant virus 
which is unable to counteract IFN response from host (100). The seven lncRNAs used in our 
studies were also induced by type I IFN. 
 
4.7 Function of TAPSAR1 
Functional analysis of one of the highly upregulated lncRNA TAPSAR1 indicated that it 
acts as pro-viral for influenza virus replication. LncRNAs NRAV (48) and VIN (100) have been 
shown to reduce virus replication. VIN is required for influenza virus replication and its deletion 
reduces virus yield and protein synthesis however the exact mechanism is yet to be clarified. 
NRAV is involved in the downregulation of Mx1 and interferon induced transmembrane protein 




response during influenza virus infection. TAPSAR1 knockdown led to the reduction in virus titer 
and protein synthesis but had almost no effect on viral mRNA translation or protein stability. This 
suggests that TAPSAR1 may be involved in late stages of virus replication such as synthesis 
and/or export of virus proteins. 
 
4.8 LncRNA location and neighbouring genes 
Localization of lncRNAs in cells may provide significant information about how their 
functions are achieved. lncRNA in the cytoplasm such as DANCR can compete for miRNA 
binding sites (101). lncRNAs in the nucleus can regulate gene transcription through chromatin 
modification (102). NEAT1 and MALAT1 are present in paraspeckles and nuclear speckles 
inside the nucleus, respectively (51) (103). NEAT1 is responsible for maintaining structure of 
paraspeckles (104) as well as regulation of transcription of IL-8 genes (51). MALAT1 is known 
to regulate genes associated with lung cancer metastasis (105). Another nuclear lncRNA, NRAV 
functions as a histone modification factor of anti-viral genes, MxA and IFITM3 (48) TAPSAR1 
is predominantly located in the nucleus of A549 cells which suggest that it may play a role in 
transcription, chromatin remodeling or post-transcriptional processing (106). However, exact role 
and location inside the nucleus of TAPSAR1 during influenza virus infection remains to be 
determined. 
Human TAPSAR1 has two neighboring genes, TAP1 and PSMB8. Even though PSMB8 
was induced by PR/8, we did not observe any significant changes in PSMB8 level after 
knockdown of TAPSAR1. We could not detect TAP1 in control or PR/8-infected lung epithelial 
A549 cells using real-time PCR. TAP1 and PSMB8 have previously been shown to be induced by 







4.9 IP10 in influenza virus infection 
Our present studies showed that the reduction of TAPSAR1 level by 38% resulted in 60% 
decrease in IP10 expression in PR/8-infected A549 cells. IP10 also called C-X-C motif 
chemokine 10 (CXCL10) is an interferon-γ that functions in monocyte stimulation, natural killer 
and activated T cell migration (111). IP10 induction is critical for a proper adaptive immune 
response to promote inflammation and recruit lymphocytes to the site of infection. Although 
neutrophils have been identified as a source of IP10 (112, 113) during influenza virus-induced 
respiratory syndrome, influenza H1N1 virus induces a high level of IP10 in human lung epithelial 
cells (114-116) and human lung slice culture (117). Mortality caused by influenza virus is largely 
associated with cytokine storm due to hyperactivation of immune system (118). Higher levels of 
IP10 in the serum of 2009 swine-origin influenza virus infected patients was observed (119). A 
high level of IP10 and other pro-inflammatory cytokine mRNAs was correlated to acute lung 
injury (114) whereas lower levels of IP10 have been correlated to hepatitis C virus clearance 
(120). It has been also shown that IP10 stimulates HIV replication (121). The gene deletion or 
antibody neutralization of IP10 protects the mice from influenza virus infection (119). CXCR3 is 
a receptor for IP10 and its deletion also improves the severity of influenza virus–induced lung 
injury (112). We speculate that TAPSAR1 involvement in influenza virus replication may be 









5.1 Wnt signaling inhibitor iCRT14 and influenza virus  
Present study provides evidence that inhibition of Wnt/β-catenin signaling limits 
influenza virus infection by reducing influenza virus replication independent of the IFN response. 
Inhibitor of this pathway iCRT14 was able to inhibit the RNA synthesis of influenza virus. 
ICRT14 was also able to successfully inhibit virus replication of two different strains of influenza 
virus in primary alveolar epithelia cells. Wnt/β-catenin inhibitors may be used to develop a new 
class of antivirals targeting host factors.  
5.2 iCRT14 protects mice from influenza virus infection 
Wnt3a conditional media increased influenza virus replication in mice. iCRT14 partially 
protects mice from lethal and sub-lethal influenza virus challenges. Histopathology related to 
influenza virus induced-pneumonia was also partially attenuated by iCRT14.   
5.3 LncRNA and influenza virus 
 LncRNA were dysregulated by influenza virus infection as revealed by RNA-seq 
approach. Some lncRNA expression was also induced by different influenza virus strains and 




pathways related to immune signaling, cellular components and biological processes were highly 
involved.  
5.4 Effect of lncRNA TAPSAR1 knockdown on influenza virus replication.  
The knockdown of lncRNA TAPSAR1 inhibited influenza virus replication and reduced 
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